Strategy for treatment of fibrosis in systemic sclerosis: Present and future (Q38701990)

5 September 2017

title

Strategy for treatment of fibrosis in systemic sclerosis: Present and future (English)

1 reference

5 September 2017

Koichi Yanaba

1 reference

5 September 2017

publication date

1 January 2016

1 reference

The Journal of Dermatology

5 September 2017

published in

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

page(s)

46-55

1 reference

Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma)

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Mortality in systemic sclerosis: an international meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Isolated pulmonary hypertension in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Improvement in skin thickening in systemic sclerosis associated with improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Cellular infiltrates in scleroderma skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Recent advances on pathogenesis and therapies in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Determinants of morbidity and mortality of systemic sclerosis in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Survival and causes of death in 366 Hungarian patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

B-lymphocyte contributions to human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

IL-6 as a keystone cytokine in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Interleukin 6 in systemic sclerosis and potential implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Influence of the IL6 gene in susceptibility to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Stem cell therapies for systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

mTOR--beyond transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Pirfenidone: in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Lung Fibrosis is Ameliorated by Pirfenidone Fed in Diet After the Second Dose In A Three-Dose Bleomycin-Hamster Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic scl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1346-8138.13026

21 January 2018

Identifiers

DOI

10.1111/1346-8138.13026

1 reference

5 September 2017

1 reference